COMPANY
Past trials only
Keywords: oncology cancer Glioblastoma Multiforme ICT-107 ICT-121 DC vaccine
Location: Nashville, TN · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start 3: Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma source ↗
- Trial start Phase 1: A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma source ↗
- Trial start Phase 2: A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | 3 | Suspended | 2024-12 | 2025-12 (estimated) |
| NCT02049489 | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | Phase 1 | Completed | 2013-12 | 2017-03 (actual) |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | Phase 2 | Completed | 2011-01 | 2013-12 (actual) |
